Quarterly ResultMay 12, 2026, 04:27 PM
LB Pharmaceuticals Q1 Net Loss $19.1M; $365.6M Cash Funds into Q2 2029
AI Summary
LB Pharmaceuticals Inc. reported a net loss of $19.1 million for the first quarter ended March 31, 2026, with research and development expenses increasing to $14.6 million. The company initiated pivotal Phase 3 and Phase 2 clinical trials for LB-102 in schizophrenia and bipolar depression, respectively, and plans a Phase 2 trial for adjunctive MDD in early 2027. Following a $100 million private placement, LB Pharmaceuticals holds $365.6 million in cash, cash equivalents, and marketable securities, expected to fund operations into Q2 2029 through multiple clinical milestones.
Key Highlights
- Net loss was $19.1 million for Q1 2026, compared to $5.3 million for Q1 2025.
- Research & development expenses increased to $14.6 million for Q1 2026, up $11.2 million YoY.
- General & administrative expenses rose to $7.5 million for Q1 2026, up $4.5 million YoY.
- Cash, cash equivalents, and marketable securities totaled $365.6 million as of March 31, 2026.
- Cash position is expected to fund operations into Q2 2029, through multiple clinical milestones.
- Initiated pivotal Phase 3 NOVA-2 trial for LB-102 in schizophrenia, with topline data expected H2 2027.
- Initiated Phase 2 ILLUMINATE-1 trial for LB-102 in bipolar 1 depression, with topline data expected Q1 2028.
- Completed a $100 million private placement in February 2026, yielding net proceeds of $93.8 million.